中文

News & Events

dMed sponsored 2017 DIA Quantitative Science Forum successfully held
2017-08-30Return>>

dMed sponsored 2017 DIA Quantitative Science Forum, held in Beijing on August 21, 2017. The theme of the forum is Data Science in Regulatory Decision Making. More than 200 statisticians, clinicians, data management experts, regulatory scientists and quantitative science experts from industry and academia, from home and abroad, gathered together. The Forum focused on hot topics, such as drug consistency evaluation, MRCT, development and evaluation in biosimilars products, real world research, etc.




Dr. Zibao Zhang of dMed, as a member of the organizing committee of the Forum, chaired in three parallel sessions, including "Challenges and solutions to innovative biotech companies in China", "Updates of CDISC standard and data submission requirements from USFDA, PMDA and CFDA" and "Risk based monitoring and site inspection readiness". With Zibao's facilitation, the domestic and global experts had valuable discussions and analysis on these topics.




Jack Li, Director of Biostatistics and Programming of dMed, as the keynote speaker, had two impressive speeches on the forum, focusing on "Drug-development challenges to Chinese innovative Biotech companies-From CRO's perspective" and "Implementation of Bayesian method in dose-finding trial design".




Dr. Jonathan Ma, Chief Data Scientist of dMed, was also on the forum panel. Jonathan was asked "what is the difference of challenges for Chinese innovative biotech companies and MNCs" and "how to play the role of leadership as a statistician in drug development" He said, "limited resource in small biotech companies and too many rules in big pharmaceutical companies are the different challenges", Jonathan also explicitly pointed out that "proactive communication is critical for a statistician". His viewpoints were echoed by the participants.


This is the most dynamic time for new drug innovation in China. Innovative Biotech companies should actively rise to the challenges, as well as seize the opportunities. dMed is willing to cooperate with different organizations and companies, and strive for promotion of the new drug innovation and improvement of the quality of clinical trials in China.


298 Xiangke Road, 3/F, 301-305, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201210, China
Tel: +86 21 5090 0085 Fax: +86 21 6875 5515
沪ICP备16041651号-1 Copyright © 2016 dMed All Rights Reserved
沪公网安备 31011502005403号